 |
English
|
正體中文
|
简体中文
|
Items with full text/Total items : 12145/12927 (94%)
Visitors : 914121
Online Users : 1277
|
|
|
Loading...
|
Please use this identifier to cite or link to this item:
http://ir.nhri.org.tw/handle/3990099045/13592
|
| Title: | How may ramucirumab help improve treatment outcome for patients with gastrointestinal cancers? |
| Authors: | Chen, MH;Lu, SN;Chen, CH;Lin, PC;Jiang, JK;D'Yachkova, Y;Lukanowski, M;Cheng, R;Chen, LT |
| Contributors: | National Institute of Cancer Research |
| Abstract: | Simple Summary Malignancies of the gastrointestinal (GI) tract are among the five most common cancers worldwide. Despite significant therapeutic improvements over the last decade, this group of cancers is characterized by high recurrence rates and a dismal prognosis. There is an urgent need for new therapeutic approaches. New blood vessel formation is pivotal to tumor growth. Ramucirumab (Cyramza(R) (Eli Lilly and Company, IN, USA)) is a monoclonal antibody that specifically binds to and blocks the activation of vascular endothelial growth factor (VEGF) receptor 2. Ramucirumab is approved for a number of GI tract malignancies either as monotherapy or in combination with chemotherapies. Here, we give an overview of the survival and tolerability data for ramucirumab from phase 3 randomized controlled clinical trials in GI cancers including those from important pre-specified patient subgroups and evidence from real clinical practice worldwide. Our aim is to summarize these data to demonstrate how ramucirumab may help improve treatment outcome for patients with GI cancers. GI cancers are characterized by high recurrence rates and a dismal prognosis and there is an urgent need for new therapeutic approaches. This is a narrative review designed to provide a summary of the efficacy as measured by overall survival, progression free survival, and safety data from phase 3 randomized controlled GI clinical trials of ramucirumab including those from important pre-specified patient subgroups and evidence from real clinical practice worldwide. Quality of life (QOL) is discussed where data are available. Our aim was to summarize the efficacy and safety of ramucirumab in the treatment of GI cancers using these existing published data with a view to demonstrating how ramucirumab may help improve treatment outcome for patients with GI cancers. The data indicate that ramucirumab is efficacious, safe, and tolerable across the intent-to-treat patient populations as a whole and across several pre-specified subgroups, even those whose disease is traditionally more difficult to treat. Furthermore, survival outcomes observed in real-world clinical practice demonstrate similar data from phase 3 clinical trials even in patients with complications, suggesting that the benefits of ramucirumab translate in actual clinical practice. |
| Date: | 2021-07-15 |
| Relation: | Cancers. 2021 Jul 15;13(14):Article number 3536. |
| Link to: | http://dx.doi.org/10.3390/cancers13143536 |
| JIF/Ranking 2023: | http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=2072-6694&DestApp=IC2JCR |
| Cited Times(WOS): | https://www.webofscience.com/wos/woscc/full-record/WOS:000676186000001 |
| Cited Times(Scopus): | https://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=85110217383 |
| Appears in Collections: | [陳立宗] 期刊論文
|
Files in This Item:
| File |
Description |
Size | Format | |
|---|
| ISI000676186000001.pdf | | 7113Kb | Adobe PDF | 216 | View/Open |
|
All items in NHRI are protected by copyright, with all rights reserved.
|
